{"organizations": [], "uuid": "280bcecd91a2fc6954aeead91d92f8de874f1b6b", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180220.html", "section_title": "Archive News &amp; Video for Tuesday, 20 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-aimmune-therapeutics-phase-3-palis/brief-aimmune-therapeutics-phase-3-palisade-trial-of-ar101-meets-primary-endpoint-in-patients-with-peanut-allergy-idUSASB0C6CG", "country": "US", "domain_rank": 408, "title": "BRIEF-Aimmune Therapeutics' Phase 3 Palisade Trial Of Ar101 Meets Primary Endpoint In Patients With Peanut Allergy", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.018, "site_type": "news", "published": "2018-02-20T20:28:00.000+02:00", "replies_count": 0, "uuid": "280bcecd91a2fc6954aeead91d92f8de874f1b6b"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-aimmune-therapeutics-phase-3-palis/brief-aimmune-therapeutics-phase-3-palisade-trial-of-ar101-meets-primary-endpoint-in-patients-with-peanut-allergy-idUSASB0C6CG", "ord_in_thread": 0, "title": "BRIEF-Aimmune Therapeutics' Phase 3 Palisade Trial Of Ar101 Meets Primary Endpoint In Patients With Peanut Allergy", "locations": [], "entities": {"persons": [], "locations": [{"name": "palisade", "sentiment": "none"}], "organizations": [{"name": "brief-aimmune therapeutics", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "palisade", "sentiment": "negative"}, {"name": "aimmune therapeutics inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 20 (Reuters) - Aimmune Therapeutics Inc:\n* AIMMUNE THERAPEUTICS’ PIVOTAL PHASE 3 PALISADE TRIAL OF AR101 MEETS PRIMARY ENDPOINT IN PATIENTS WITH PEANUT ALLERGY\n* AIMMUNE THERAPEUTICS’ PIVOTAL PHASE 3 PALISADE TRIAL OF AR101 MEETS PRIMARY ENDPOINT IN PATIENTS WITH PEANUT ALLERGY\n* AIMMUNE THERAPEUTICS-LOWER-BOUND OF 95% CONFIDENCE INTERVAL OF DIFFERENCE BETWEEN TREATMENT ARMS AT PRIMARY ENDPOINT WAS 53.0, GREATLY EXCEEDING PRE-SPECIFIED THRESHOLD OF 15%\n* AIMMUNE THERAPEUTICS-AMONG PATIENTS AGES 4-17 WHO COMPLETED TREATMENT WITH AR101, 96.3% TOLERATED A 300-MG DOSE OF PEANUT PROTEIN IN EXIT FOOD CHALLENGE\n* AIMMUNE THERAPEUTICS SAYS 2.4% OF AR101 PATIENTS AGES 4-17 AND 0.8% OF PLACEBO PATIENTS EXPERIENCED SERIOUS ADVERSE EVENTS Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-20T20:28:00.000+02:00", "crawled": "2018-02-21T21:35:05.027+02:00", "highlightTitle": ""}